H.C. Wainwright initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $58 price target The firm views the company’s lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback